Afleveringen
-
InpharmD's EBM podcast focuses on commonly asked drug information questions. Every day, our queue gets tons of new questions asked from providers all around the country. One question that’s been garnering a lot of views from our users right now is which atypical antipsychotics are associated with the lowest and highest risk of QT prolongation.
-
Join InpharmD as we discuss the role of apixaban in peripheral artery disease.
-
Zijn er afleveringen die ontbreken?
-
Join InpharmD as we discuss the safety and efficacy of two FDA-approved RSV vaccines, Arexvy and Abrysvo.
-
Join us as we discuss the data surrounding newly approved antifungal agent, rezafungin. Interested in learning more? Join our CE on rezafungin on July 27th at 12:00 PM EST - open to all pharmacists!
-
Every month, InpharmD creates a continuing-education (CE) class on the most commonly asked drug information question and the related evidence. Our podcast offers a sneak peak into our CE as we briefly discuss the topic.
Episode-2 looks at the safety and efficacy of lecanemab in the treatment of Alzheimer’s dementia.
-
Join us as we discuss the evidence surrounding tirzepatide for weight loss in diabetic patient populations.
-
Tune in as we discuss the PROVENT trial and the on-going TACKLE trial to determine whether or not Evusheld can increase cardiovascular events.
-
A regression analysis conducted in Israel showed that a fourth dose appeared to increase the protection against severe illness relative to three doses that were administered more than 4 months earlier. Further studies are needed before applying this to a larger population.
-
A cohort study conducted to estimate the rate of breast cancer overdiagnosis in contemporary mammography practice accounting for the detection of nonprogressive cancer.
-
A retrospective study conducted to assess for any decrease in mortality associated with the use of the BNT162b2 (BioNTech, Pfizer vaccine) booster.
-
The first in-human, phase 1, randomized, double-blind, placebo-controlled study conducted to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of molnupiravir in healthy subjects.
- Laat meer zien